Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world - Kapelios, CJ; Lainscak, M; Savarese, G; Laroche, C; Seferovic, P; Ruschitzka, F; Coats, A; Anker, SD; Crespo-Leiro, MG; Filippatos, G; Piepoli, MF; Rosano, G; et al. (European journal of heart failure, 2019)